Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody diagnostics and therapeutics - Immunomedics

Drug Profile

Research programme: antibody diagnostics and therapeutics - Immunomedics

Alternative Names: (14)-3s; (19)-3s; (E1)-3s; (M1)-3s; 20-(74)-(74) antibody; 20-2b; 74-(20)-(20) antibody; Anti-CD19 antibodies; anti-CD20/CD74 antibodies; bsMAb; Ck-20-2b; CK-22-(20)-(20); E1.BB.3z-92MI; MAb-Rap; TF 12; TF 3; TF 4; TF 5; Veltuzumab-interferon-α2b conjugate

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Bispecific antibodies; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Recombinant fusion proteins; Ribonucleases
  • Mechanism of Action Apoprotein stimulants; Glycoprotein modulators; Ionising radiation emitters; Mitosis inhibitors; Protein synthesis inhibitors; Ribonuclease stimulants; T lymphocyte stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Gastric cancer; Lymphoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 28 Jan 2021 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (Parenteral)
  • 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
  • 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top